06-Feb-2020

Lupus Anticoagulant Testing Market Overview, Segmentation, Top Key Companies, Value Chain, Market Size and Trends

VALLEY COTTAGE, N.Y. – Lupus anticoagulants (LA) are antibodies directed against phospholipid-binding proteins that prolong phospholipid-dependent coagulation assays. Lupus anticoagulant testing is a special blood test to find out if certain antibodies or proteins that cause blood-clotting disorders are present. Persistent lupus anticoagulant testing positivity is a risk factor for the occurrence and recurrence of venous/arterial thromboembolism and/or pregnancy morbidity and qualifies the patient for lupus anticoagulant testing.

The antibodies to be tested are present in about 2-4% of the general population and may develop in people with no known risk factors. Initial lupus anticoagulant testing typically involves one or more tests that depend on phospholipid-containing reagents, usually partial thromboplastin time (PTT), the LA-sensitive PTT (known as PTT-LA) or dilute Russell viper venom test (DRVVT). The undiagnosed patients are at a constant risk of developing antiphospholipid syndrome, a disease that provokes blood clots in arteries and veins.

Download the sample copy of Report with table of contents and Figures @ https://www.futuremarketinsights.com/reports/sample/rep-gb-10746

Lupus Anticoagulant Testing: Market Drivers and Restrains

Recurrent thrombosis in patients with blood disorders is expected to rise the demand for lupus anticoagulant testing. According to NIH, it is estimated that 20 percent of individuals younger than age 50 who have a stroke have antiphospholipid syndrome which would rise the size of lupus anticoagulant testing market with rising awareness. Blood disorders like anemia and bleeding disorders such as hemophilia, blood clots, and blood cancers such as leukemia, lymphoma, and myeloma are on rise. Von Willebrand disease (VWD) is a bleeding disorder in which blood doesn’t clot properly. Between 2012 and 2016, more than 14,600 men, women, and children were seen at hemophilia treatment centers for treatment of VWD in the U.S which is expected to increase the demand for lupus anticoagulant testing. The number of traumatic injuries and wounds are on a rise which could be a reason for rising number of lupus anticoagulant testing done annually to confirm blood disorders.

Lupus Anticoagulant Testing Market: Overview

The lupus anticoagulant testing market is structured differently depending on the regions. North America and Europe has a number of diagnostic laboratories to avail for lupus anticoagulant testing. On the other hand, the existence of the condition is not known. The dependence on hospitals for primary blood related disorders in remote rural areas in Asia-Pacific and African countries is not observed in the developed lupus anticoagulant testing markets. Blood clots observed in patients with blood related cancers such as leukemia, lymphoma, and myeloma are expected to fuel the demand for lupus anticoagulant testing.

Preview Analysis of Lupus Anticoagulant Testing Market : Global Industry Analysis 2014 – 2018 and Opportunity Assessment 2019 – 2029: https://www.futuremarketinsights.com/reports/lupus-anticoagulant-testing-market

Lupus Anticoagulant Testing Market: Region-wise Outlook

Globally, North America is anticipated to be the largest contributor of lupus anticoagulant testing market. Increase in epidemics related to bleeding disorders in low-income countries contribute to the lupus anticoagulant testing market. East and South Asia is anticipated to be the second largest market in lupus anticoagulant testing. Europe will also contribute generously to lupus anticoagulant testing market with rising healthcare spending on diseases related to lupus anticoagulant testing market. Middle East & Africa lupus anticoagulant testing market growth is hindered due to high poverty in the region coupled with lower GDP to healthcare spending ratio and lack of healthcare infrastructure.

Lupus Anticoagulant Testing Market: Segmentation –

Lupus Anticoagulant Testing Segmentation by Test Type:

Prothrombin Time (PT)
Activated Partial Thrombopl Time
Dilute Russells Viper Venom Time
Coagulation Factor VIII Assay

Buy this report @ https://www.futuremarketinsights.com/checkout/10746

Lupus Anticoagulant Testing Segmentation by End User:

Hospitals
Clinics
Diagnostic Laboratories
Online Pharmacy

Lupus Anticoagulant Testing Market: Key Players

Some of the key players present in global lupus anticoagulant testing market include Becton Dickinson, Abbott, AstraZeneca plc, F. Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Inc, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V. and leading diagnostic laboratories within respective countries. With active mergers and acquisitions, the lupus anticoagulant testing market is changing the structure and presence of various small players active in the lupus anticoagulant testing market.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-10746

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us
Mr. Abhishek Budholiya
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44-(0)-20-7692-8790
Sales:sales@futuremarketinsights.com
Press Office: Press@futuremarketinsights.com
Blog: Market Research Blog
Website: https://www.futuremarketinsights.com/

Editor Details

Company:
- MARKITWIRED
Website:
- MARKITWIRED

Last Updated: 06-Feb-2020